Diabetes Prevention Program Pilot

NCT ID: NCT04651816

Last Updated: 2023-09-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-25

Study Completion Date

2023-08-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This initiative, which is a partnership between State College area Penn State Health ambulatory care clinics located off campus in the State College area, has two primary goals: 1) improve the health and quality of life of Penn State Health patients with pre-diabetes and 2) decrease associated health care costs due to type 2 diabetes and its complications. The results from the study may serve as a model for additional chronic disease prevention programs to implement in additional Penn State Health clinics in the future.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Through this initiative, providers in Penn State Health ambulatory health care clinics (PSH clinics) will identify pre-diabetic patients to take part in a Diabetes Prevention Program (DPP), modeled after the Centers for Disease Control's (CDC) program.

The DPP is a CDC-recognized lifestyle change program developed specifically to prevent type 2 diabetes. It is designed for people who have prediabetes or are at risk for type 2 diabetes, but who do not already have diabetes. We will be using the DPP distance learning program which allows online delivery of classes. A trained lifestyle coach leads the program to help subjects change certain aspects of their lifestyle, like eating healthier, reducing stress, and getting more physically activity. The program also includes group support. The DPP is a year-long program focused on long-term changes and lasting results. Key components of the program include a CDC-approved curriculum with lessons, handouts, and other resources; a lifestyle coach, specifically trained to lead the program; and a support group of people with similar goals and challenges.

To that end, this study has multiple arms that will test whether participation in the PSH DPP - and exposure to motivational messages that encourage physical activity or participation in lotteries, an increasingly common strategy for behavioral motivation, - significantly improves program retention and health-related outcomes, compared to those who only participate in the PSH DPP.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre-diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

FACTORIAL

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants
Participants will not know what intervention group they will be assigned to (motivational messaging, incentives or control group).

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Control PSH DPP only

This group will be enrolled the PSH DPP program. There will be two cohorts for this arm.

Group Type ACTIVE_COMPARATOR

DPP Program

Intervention Type BEHAVIORAL

All Participants will be enrolled in the DPP program.

Treatment 1 Financial Incentives A

This group will receive gift cards as financial incentive to participate in the PSH DPP program. There will be two cohorts for this arm.

Group Type EXPERIMENTAL

Financial Incentives

Intervention Type BEHAVIORAL

Participants will be entered into a lottery to receive a gift card for class attendance.

DPP Program

Intervention Type BEHAVIORAL

All Participants will be enrolled in the DPP program.

Treatment 2 Financial Incentives B

This group will receive gift cards as financial incentive to participate in the PSH DPP program. There will be two cohorts for this arm.

Group Type EXPERIMENTAL

Financial Incentives

Intervention Type BEHAVIORAL

Participants will be entered into a lottery to receive a gift card for class attendance.

DPP Program

Intervention Type BEHAVIORAL

All Participants will be enrolled in the DPP program.

Treatment 3 Motivational Text Messaging

This group will receive text messages with motivational messages while participating in the PSH DPP program. There will be two cohorts for this arm.

Group Type EXPERIMENTAL

Motivational Message

Intervention Type BEHAVIORAL

Participants will be sent motivational messages through out their participation in the PSH DPP program.

DPP Program

Intervention Type BEHAVIORAL

All Participants will be enrolled in the DPP program.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Financial Incentives

Participants will be entered into a lottery to receive a gift card for class attendance.

Intervention Type BEHAVIORAL

Motivational Message

Participants will be sent motivational messages through out their participation in the PSH DPP program.

Intervention Type BEHAVIORAL

DPP Program

All Participants will be enrolled in the DPP program.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Be at least 18 years old and under age 65 AND
2. Body Mass Index ≥25 kg/m2 (≥23 kg/m2 if Asian) AND
3. Not be pregnant at time of enrollment AND
4. Have no previous diagnosis of type 1 or type 2 diabetes AND
5. Have a blood test result in the prediabetes range within the past year, meeting one of these specifications:

1. Hemoglobin A1c: 5.7-6.4%, OR
2. Fasting plasma glucose : 100-125 mg/dL, OR
3. Two-hour plasma glucose (after a 75-gm glucose load): 140-199 mg/dL, OR
4. Have a previous clinical diagnosis of gestational diabetes mellitus (GDM), AND
6. Not in hypertensive crisis with systolic over 180 and/or diastolic over 120
7. Be an established patient at a Penn State Health clinic in State College, PA (i.e. have at least one visit in past 18 months) AND
8. Fluent in English AND
9. Own and carry an iPhone (running iOS version 10 or higher) or Android (running operating system 7 or higher) smartphone during waking hours
10. Internet access
11. Tablet or desktop/laptop computer with webcam for classes
12. Active email address

Exclusion Criteria

1. Under 18 years old and over age 65
2. Body Mass Index \<25 kg/m2 (\<23 kg/m2 if Asian)
3. Pregnant at the time of enrollment
4. Previous diagnosis of type 1 or type 2 diabetes
5. Have a blood test result within the past year meeting one of these specifications:

1. Hemoglobin A1c: not in range of 5.7-6.4%
2. Fasting plasma glucose: not in range of 100-125 mg/dL
3. Two-hour plasma glucose (after a 75-gm glucose load): not in range of 140-199 mg/dL
4. No previous clinical diagnosis of gestational diabetes
6. Active hypertensive crisis with systolic over 180 and/or diastolic over 120 (patients in this category would be referred to primary care provider for immediate visit)
7. Not be an established patient at a Penn State Health clinic in State College, PA (i.e. have not had at least one visit in the past 18 months)
8. Not fluent in English
9. Not own and carry an iPhone (running iOS version 10 or higher) or Android (running operating system 7 or higher) smartphone during waking hours.
10. Decisional impairment
11. Prisoner status
12. Actively taking any of the following drug classes: Biguanides, Sulfonylureas (SU), Thiazolidendiones (TZD), Meglitinides, Alpha-glucosidase inhibitors, Dipetidyl Peptidase-IV (DPP4) inhibitors, Insulin , Sodiumglucose transporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) .
13. Anyone who does not have internet access
14. Anyone who does not have tablet or desktop/laptop computer with webcam
15. Anyone who does not have an active email address
Minimum Eligible Age

18 Years

Maximum Eligible Age

64 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Milton S. Hershey Medical Center

OTHER

Sponsor Role collaborator

Penn State University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dennis P. Scanlon

Distinguished Professor of Health Policy and Administration, Director of the Center for Health Care and Policy Research

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Penn State Health Medical Group -- Park Avenue

State College, Pennsylvania, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

00010222

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Encourage Healthy Families
NCT01823367 COMPLETED NA
Diabetes Prevention Program
NCT00004992 COMPLETED PHASE3
Penn Medicine Healthy Heart
NCT06062394 RECRUITING NA